Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Avelumab + Valproic acid|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 73||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|Valproic acid||Stavzor||Depacon|Valproate Sodium|Depakene||HDAC Inhibitor 38||Valproic acid inhibits HDAC activity, potentially resulting in decreased angiogenesis, increased tumor cell differentiation, and reduced tumor growth (PMID: 11742974, PMID: 14978230). Valproic acid is FDA-approved for use in treating seizures (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03357757||Phase II||Avelumab + Valproic acid||Avelumab With Valproic Acid in Virus-associated Cancer (LATENT)||Recruiting||CAN||0|